Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease
Summary
- Clinical trial data suggest raltegravir, elvitegravir, dolutegravir, bictegravir, and maraviroc have little effect on lipid levels[Sierra-Madero 2010; Rockstroh 2013; Sax 2012; DeJesus 2012; Cooper 2010; Raffi 2013; Walmsley 2013; Molina 2015; Gallant 2017; Sax 2017; Daar 2017]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Dyslipidemia, Treatment Complications